作者
Min Xie, Yongli Kong, Wei Tan, Herman May, Pavan K Battiprolu, Zully Pedrozo, Zhao V Wang, Cyndi Morales, Xiang Luo, Geoffrey Cho, Nan Jiang, Michael E Jessen, John J Warner, Sergio Lavandero, Thomas G Gillette, Aslan T Turer, Joseph A Hill
发表日期
2014/3/11
期刊
Circulation
卷号
129
期号
10
页码范围
1139-1151
出版商
Lippincott Williams & Wilkins
简介
Background
Reperfusion accounts for a substantial fraction of the myocardial injury occurring with ischemic heart disease. Yet, no standard therapies are available targeting reperfusion injury. Here, we tested the hypothesis that suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor approved for cancer treatment by the US Food and Drug Administration, will blunt reperfusion injury.
Methods and Results
Twenty-one rabbits were randomly assigned to 3 groups: (1) vehicle control, (2) SAHA pretreatment (1 day before and at surgery), and (3) SAHA treatment at the time of reperfusion only. Each arm was subjected to ischemia/reperfusion surgery (30 minutes coronary ligation, 24 hours reperfusion). In addition, cultured neonatal and adult rat ventricular cardiomyocytes were subjected to simulated ischemia/reperfusion to probe mechanism. SAHA reduced infarct size and partially rescued systolic …
学术搜索中的文章
M Xie, Y Kong, W Tan, H May, PK Battiprolu, Z Pedrozo… - Circulation, 2014